UnitedHealth Group's stock has risen from $300 to around $440-$450, reflecting a recovery in margins and key business areas like Medicare Advantage and Optum Health. However, the current valuation leaves little room for safety, as the market already prices in this recovery and future growth. The analyst now rates the stock as a Sell, citing risks from ongoing medical cost inflation and challenges in Commercial and Medicaid segments. The valuation model suggests a potential 34% decline to an intrinsic value of $245.60 per share based on normalized assumptions and consensus forecasts.
UnitedHealth Group's stock is trading at USD 378.84 on Pluang, slightly up by 0.07% as of Oct 06, 2026 20:33 WIB. The stock's market cap stands at $339.81 billion with a dividend yield of 2.45%, and most Pluang investors hold their shares for about 97 days.
